<?xml version="1.0" encoding="UTF-8"?>
<table-wrap position="float" id="tbl0005">
 <label>Table 1</label>
 <caption>
  <p>Representative antiviral nanoagents in published papers.</p>
 </caption>
 <alt-text id="at0015">Table 1</alt-text>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th align="left">ENMs</th>
    <th align="left">Size</th>
    <th align="left">Surface modification / antiviral agent</th>
    <th align="left">Virus
     <xref rid="tblfn0005" ref-type="table-fn">a</xref>
    </th>
    <th align="left">Study</th>
    <th colspan="2" align="left">Mechanism</th>
    <th align="left">Ref.</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="left" valign="middle" rowspan="2">Ag NPs</td>
    <td align="left">16 nm</td>
    <td align="left">Polyvinylpyrrolidone / bovine serum albumin</td>
    <td align="left">HIV-1</td>
    <td align="left">
     <italic>In vitro</italic>
    </td>
    <td align="left" valign="middle" rowspan="4">Virus or host cell surface receptor interactions</td>
    <td align="left">Binding to gp120 glycoprotein knobs on HIV-1 surface.</td>
    <td align="left">[
     <xref rid="bib0060" ref-type="bibr">12</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">50 nm</td>
    <td align="left"/>
    <td align="left">HBV</td>
    <td align="left">
     <italic>In vitro</italic>
    </td>
    <td align="left">Impeding the transcription of viral RNA by directly binding to HBV DNA.</td>
    <td align="left">[
     <xref rid="bib0070" ref-type="bibr">14</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">GO</td>
    <td align="left"/>
    <td align="left"/>
    <td align="left">HSV-1</td>
    <td align="left">
     <italic>In vitro</italic>
    </td>
    <td align="left">Mimicking the cell surface receptor heparan sulfate to inhibit HSV binding to host cells.</td>
    <td align="left">[
     <xref rid="bib0080" ref-type="bibr">16</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">Au NPs</td>
    <td align="left">2.3 nm</td>
    <td align="left">Ligands containing undecane sulfonic acid</td>
    <td align="left">HSV, HPV, RSV, DENV</td>
    <td align="left">
     <italic>In vivo</italic>, 
     <italic>in vitro</italic>
    </td>
    <td align="left">Au NPs coated with undecane sulfonic acid mimicking the heparin sulfate proteoglycans to prevent the virusâ€“cell interaction.</td>
    <td align="left">[
     <xref rid="bib0090" ref-type="bibr">18</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" rowspan="2">PLGA NPs</td>
    <td align="left">395 nm</td>
    <td align="left">Acyclovir</td>
    <td align="left">HSV</td>
    <td align="left">
     <italic>In vivo</italic>, 
     <italic>in vitro</italic>
    </td>
    <td align="left" valign="middle" rowspan="4">Antiviral agent delivery</td>
    <td align="left">PLGA NPs loaded with acyclovir for oral delivery.</td>
    <td align="left">[
     <xref rid="bib0100" ref-type="bibr">20</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">180 nm</td>
    <td align="left">3D8 scFv antibody</td>
    <td align="left">VSV</td>
    <td align="left">
     <italic>In vivo</italic>, 
     <italic>in vitro</italic>
    </td>
    <td align="left">Cytoplasmic delivery of a monoclonal antibody with nucleic acid-hydrolyzing activity.</td>
    <td align="left">[
     <xref rid="bib0170" ref-type="bibr">34</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" rowspan="2">Liposome</td>
    <td align="left">150 nm</td>
    <td align="left">Suramin</td>
    <td align="left">NV</td>
    <td align="left">
     <italic>In vitro</italic>
    </td>
    <td align="left">Delivery the suramin-loaded liposome to inhibit NV polymerases.</td>
    <td align="left">[
     <xref rid="bib0110" ref-type="bibr">22</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">124 nm</td>
    <td align="left">Stearylamine</td>
    <td align="left">BV, HSV-1</td>
    <td align="left">
     <italic>In intro</italic>
    </td>
    <td align="left">Cationic liposomes with incorporated stearylamine inhibit viral infectivity.</td>
    <td align="left">[
     <xref rid="bib0175" ref-type="bibr">35</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" rowspan="4">Au NPs</td>
    <td align="left">5, 50, 100 nm</td>
    <td align="left">Thiol cysteamine</td>
    <td align="left">HCV</td>
    <td align="left">
     <italic>In vivo</italic>, 
     <italic>in vitro</italic>
    </td>
    <td align="left" valign="middle" rowspan="4">Nanovaccines</td>
    <td align="left">DNA segment specific to HCV core gene conjugated on the AuNPs to simulate the immune response.</td>
    <td align="left">[
     <xref rid="bib0135" ref-type="bibr">27</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">2 2, 5, 8, 12, 17, 37, 50 nm</td>
    <td align="left">FMDV peptide</td>
    <td align="left">FMDV</td>
    <td align="left">
     <italic>In vivo</italic>, 
     <italic>in vitro</italic>
    </td>
    <td align="left">C-terminus of the FMDV peptide conjugated on AuNPs to induce the magnitude of the immune response.</td>
    <td align="left">[
     <xref rid="bib0180" ref-type="bibr">36</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">20,40 nm</td>
    <td align="left">WNV envelope E protein</td>
    <td align="left">WNV</td>
    <td align="left">
     <italic>In vivo</italic>, 
     <italic>in vitro</italic>
    </td>
    <td align="left">WNV envelope E protein coated AuNPs enhance the immune response.</td>
    <td align="left">[
     <xref rid="bib0185" ref-type="bibr">37</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">20, 40, 80 nm</td>
    <td align="left">ED III protein</td>
    <td align="left">DENV</td>
    <td align="left">
     <italic>In vivo</italic>, 
     <italic>in vitro</italic>
    </td>
    <td align="left">Serotype 2 of DENV as dengue subunit to functionalize Au NPs to induce a high level of antibody to neutralizing DENV.</td>
    <td align="left">[
     <xref rid="bib0190" ref-type="bibr">38</xref>]
    </td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn id="tblfn0005">
   <label>a</label>
   <p id="npar0005">DENV: dengue virus; VSV: vesicular stomatitis virus; BV: baculovirus; ED III: domain III of envelope glycoprotein derived from serotype 2 of dengue virus. RANTES: regulated upon activation, normal T expressed and secreted.</p>
  </fn>
 </table-wrap-foot>
</table-wrap>
